B-cell Lymphomas

14 registered clinical trials studyying B-cell Lymphomas — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With R NCT05773040	M.D. Anderson Cancer Center	Phase 1
Withdrawn	Long-term Registry of Patients Treated With Loncastuximab Tesirine NCT05160064	ADC Therapeutics S.A.	—
Withdrawn	Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas NCT03920631	Ahmed Galal, MD	Phase 1
Terminated	Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product NCT02840110	Cogent Biosciences, Inc.	—
Completed	Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas NCT02891590	Zhejiang DTRM Biopharma	Phase 1
Active Not Recruiting	CD22 Redirected Autologous T Cells for ALL NCT02650414	University of Pennsylvania	Phase 1
Completed	A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas NCT03218072	Shanghai Henlius Biotech	Phase 1
Unknown	Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas NCT02247609	Peking University	Phase 1 / Phase 2
Completed	AZD6738 First Time in Patient Multiple Ascending Dose Study NCT01955668	AstraZeneca	Phase 1
Terminated	Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912	TG Therapeutics, Inc.	Phase 1
Completed	Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma NCT01613300	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 2
Completed	Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL NCT01068392	Dong-A University Hospital	Phase 2
Completed	Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen NCT01478269	Fondazione Italiana Linfomi - ETS	—
Completed	High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement NCT00801216	Andrés José Maria Ferreri	Phase 2